Haemonetics Corp. 10-Q Summary: Quarter Ended June 28, 1997
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended June 28, 1997, for Haemonetics Corporation, a Massachusetts-based company specializing in blood management systems and plasma collection services. The company operates globally, with approximately 65% of net revenues derived from international markets. The filing includes unaudited consolidated financial statements and management's discussion and analysis.
Key Financial Metrics
| Metric | Q2 1997 | Q2 1996 |
|---|---|---|
| Net Revenues | $82.3 million | $75.5 million |
| Gross Profit | $37.1 million | $42.3 million |
| Gross Margin | 45.0% | 56.0% |
| Operating Income | $9.6 million | $14.1 million |
| Net Income | $6.5 million | $9.4 million |
| Diluted EPS | $0.24 | $0.34 |
| Cash from Operations | ($6.4) million | $1.1 million |
| Total Debt (Current + Long-term) | $55.9 million | Not explicitly stated |
| Working Capital | $107.7 million | Not explicitly stated |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 9% year-over-year (16% excluding currency effects). Growth was driven by a 9% increase in worldwide disposable sales and a 12% increase in equipment sales.
- Margin Compression: Gross margin declined significantly from 56.0% to 45.0%. Management attributes this to higher manufacturing costs (30% of the decline), unfavorable currency impacts due to a strengthening U.S. dollar (40% of the decline), and a product mix shift toward lower-margin commercial plasma disposables.
- Operating Efficiency: Operating income dropped 32% to $9.6 million. While SG&A expenses decreased as a percentage of revenue (from 30.6% to 27.3%), this was insufficient to offset the gross margin decline and startup costs associated with the new service business.
- Cash Flow Deterioration: Operating cash flow swung from a positive $1.1 million in the prior year to a negative $6.4 million. This was driven by increases in accounts receivable ($4.2 million), inventories ($3.0 million), and a decrease in accounts payable ($6.5 million).
- Debt Expansion: Long-term debt increased substantially from $10.0 million to $33.6 million as the company utilized bank borrowings to fund operations and capital expenditures.
Outlook, Risks, and Management Commentary
- Liquidity Strategy: To address cash needs, the Board approved an increase in committed bank lines from $20.0 million to $40.0 million. The company utilized $24.9 million of this new capacity during the quarter.
- Capital Allocation: The company spent $7.5 million on capital expenditures, primarily for plasma business equipment and manufacturing operations. Additionally, $5.6 million was used to repurchase 318,700 shares of treasury stock.
- Currency Risk: The company faces significant exposure to foreign currency fluctuations, particularly the Japanese yen. At period end, the company held forward exchange contracts totaling $123.4 million to hedge firm sales commitments.
- Future Expectations: Management anticipates an annualized effective tax rate of approximately 35% for fiscal 1998. No specific revenue guidance was provided for the full year.
Investor Verification Checklist
- Verify the sustainability of the 11% gross margin decline and the extent to which it is driven by temporary startup costs versus permanent structural changes in product mix.
- Confirm the company's ability to service the increased debt load ($55.9 million total) given the negative operating cash flow of $6.4 million for the quarter.
- Monitor the impact of the strengthening U.S. dollar on future international revenue, which accounts for 65% of total sales.
- Assess the cash burn rate associated with the expansion of the plasma business and service operations, which drove significant increases in receivables and inventory.
- Review the remaining capacity under the new $40.0 million credit facility to ensure sufficient liquidity for ongoing capital expenditures and working capital needs.